59 research outputs found
Die nichtaxiomatisierbarkeit des unendlichwertigen PrĂ€dikatenkalkĂŒls von Ćukasiewicz
In dieser Arbeit soll eine unendlichwertige Logik untersucht werden, deren AussagenkalkĂŒl von Ćukasiewicz und Tarski [3] erstmals diskutiert wurde. Eine ausfĂŒhrliche Darstellung des PrĂ€dikatenkalkĂŒls findet man in J. D. Rutledge [6] und B. Rosser [5]. Von A. Rose und Rosser wurde die VollstĂ€ndigkeit des AussagenkalkĂŒls bewiesen [4]. SpĂ€ter wurde von Rutledge die VollstĂ€ndigkeit des einstelligen PrĂ€dikatenkalkĂŒls bewiesen, und zwar mit algebraischen Methoden, den sogenannten MV-Algebras, die von C. C. Chang [1] eingefĂŒhrt worden sind. Hier soll bewiesen werden, dass der volle unendlichwertige PrĂ€dikatenkalkĂŒl nicht axiomatisierbar ist. Genauer: es soll gezeigt werden, dass die Menge der wahren Formeln, d.h. derjenigen Formeln, die immer den Wert Eins annehmen, nicht rekursiv auf zĂ€hlbar is
Recursive analysis of singular ordinary differential equations
We investigate systems of ordinary differential equations with a parameter. We show that under suitable assumptions on the systems the solutions are computable in the sense of recursive analysis. As an application we give a complete characterization of the recursively enumerable sets using Fourier coefficients of recursive analytic functions that are generated by differential equations and elementary operations. (C) 2010 Elsevier B.V. All rights reserved
Intravenous immunoglobulin therapy in the treatment of the acute phase of chronic idiopathic thrombocytopenic purpura in adults
A prospective, open-label phase III study was carried out to evaluate the efficacy and tolerability of a preparation of virus-inactivated normal human intravenous immunoglobulin. Fifteen adult patients suffering from chronic idiopathic thrombocytopenic purpura (ITP), (basal platelet count <20x109/l), received 0.4 g/kg daily for 5 days. The increase in platelet count, reduction in hemorrhagic events, duration of platelet response, and incidence of adverse events were recorded. Fourteen out of 15 patients achieved a platelet count ?50x109/l (response rate was 93.3%), and only 2 out of 10 patients with positive baseline Rumple-Leed test remained positive after treatment (p =0.0022). Interestingly, a close inverse correlation between platelet counts and haemoglobin levels was observed. No side effects were recorded. This study provides evidence of therapeutic efficacy and the good tolerability of the immunoglobulin preparation we used in this trial, and suggests the role of haemolysis as a mechanism for the increase in platelet count
Epidemiology of inflammatory bowel disease in Mexico and Colombia: Analysis of health databases, mathematical modelling and a case-series study
Background and aims Ulcerative Colitis (UC) and CrohnĂąâŹâąs Disease (CD) have a major impact on quality of life and medical costs. The aim of the study was to estimate the prevalence, incidence and clinical phenotypes of Inflammatory Bowel Disease (IBD) cases in Mexico and Colombia. Methods We analyzed official administrative and health databases, used mathematical modelling to estimate the incidence and complete prevalence, and performed a case-series of IBD patients at a referral center both in Mexico and Colombia. Results The age-adjusted complete prevalence of UC per 100,000 inhabitants for 2015/2016 ranged from 15.65 to 71.19 in Mexico and from 27.40 to 69.97 in Colombia depending on the model considered. The prevalence of CD per 100,000 inhabitants in Mexico ranged from 15.45 to 18.08 and from 16.75 to 18.43 in Colombia. In Mexico, the age-adjusted incidence of UC per 100,000 inhabitants per year ranged from 0.90 to 2.30, and from 0.55 to 2.33 in Colombia. The incidence for CD in Mexico ranged from 0.35 to 0.66 whereas in Colombia, the age-adjusted incidence of CD ranged from 0.30 to 0.57. The case-series included 200 IBD patients from Mexico and 204 patients from Colombia. The UC/CD prevalence ratio in Mexico and Colombia was 1.50:1 and 4.5:1 respectively. In Mexico, the female/male prevalence ratio for UC was 1.50:1 and 1.28:1 for CD, while in Colombia this ratio was 0.68:1 for UC and 0.8:1 for CD. In Mexico the relapse rate for UC was 63.3% and 72.5% for CD, while those rates in Colombia were 58.2% for UC and 58.3% for CD. Conclusions The estimated burden of disease of IBD in Mexico and Colombia is not negligible. Although these findings need to be confirmed by population-based studies, they are useful for decision-makers, practitioners and patients with this condition.Fil: Ciapponi, AgustĂn. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Parque Centenario. Centro de Investigaciones en EpidemiologĂa y Salud PĂșblica. Instituto de Efectividad ClĂnica y Sanitaria. Centro de Investigaciones en EpidemiologĂa y Salud PĂșblica; ArgentinaFil: Virgilio, Sacha Alexis. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Berrueta, Mabel. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Claire Soto, Natalie. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Ciganda, Ălvaro. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Rojas Illanes, MoisĂ©s Freddy. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Rubio Martinez, Briseida. Hospital Dr. Bernardo SepĂșlveda; MĂ©xicoFil: Gamba, Johana. FundaciĂłn Universitaria Sanitas; ColombiaFil: GonzĂĄlez Salazar, Carlos Arturo. FundaciĂłn Universitaria Sanitas; ColombiaFil: Rocha RodrĂguez, JosĂ© NicolĂĄs. FundaciĂłn Universitaria Sanitas; ColombiaFil: Scarpellini, Bruno. No especifĂca;Fil: Bravo Perdomo, Ana MarĂa. No especifĂca;Fil: Machnicki, Gerardo. No especifĂca;Fil: Aldunate, Leandro. No especifĂca;Fil: De Paula, Juan. Hospital Italiano; ArgentinaFil: Bardach, Ariel Esteban. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Parque Centenario. Centro de Investigaciones en EpidemiologĂa y Salud PĂșblica. Instituto de Efectividad ClĂnica y Sanitaria. Centro de Investigaciones en EpidemiologĂa y Salud PĂșblica; Argentin
A New Heterobinuclear FeIIICuII Complex with a Single Terminal FeIIIâO(phenolate) Bond. Relevance to Purple Acid Phosphatases and Nucleases
A novel heterobinuclear mixed valence complex [Fe^IIICu^II(BPBPMP)(OAc)_2]ClO_4, 1, with the unsymmetrical N_5O_2 donor ligand 2-bis[{(2-pyridylmethyl)aminomethyl}-6-{(2-hydroxybenzyl)(2-pyridylmethyl)} aminomethyl]-4-methylphenol (H_2BPBPMP) has been synthesized and characterized. A combination of data from mass spectrometry, potentiometric titrations, X-ray absorption and electron paramagnetic resonance spectroscopy, as well as kinetics measurements indicates that in ethanol/water solutions an [Fe^III-(nu)OH-Cu^IIOH_2]+ species is generated which is the likely catalyst for 2,4-bis(dinitrophenyl)phosphate and DNA hydrolysis. Insofar as the data are consistent with the presence of an Fe_III-bound hydroxide acting as a nucleophile during catalysis, 1 presents a suitable mimic for the hydrolytic enzyme purple acid phosphatase. Notably, 1 is significantly more reactive than its isostructural homologues with different metal composition (Fe^IIIM^II, where M^II is Zn^II, Mn^II, Ni^II,or Fe^II). Of particular interest is the observation that cleavage of double-stranded plasmid DNA occurs even at very low concentrations of 1 (2.5 nuM), under physiological conditions (optimum pH of 7.0), with a rate enhancement of 2.7 x 10^7 over the uncatalyzed reaction. Thus, 1 is one of the most effective model complexes to date, mimicking the function of nucleases
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19
Background. This studyâs primary aim was to evaluate the impact of thrombotic complications on the development of secondary infections. The secondary aim was to compare the etiology of secondary infections in patients with and without thrombotic complications. Methods. This was a cohort study (NCT04318366) of coronavirus disease 2019 (COVID-19) patients hospitalized at IRCCS San Raffaele Hospital between February 25 and June 30, 2020. Incidence rates (IRs) were calculated by univariable Poisson regression as the number of cases per 1000 person-days of follow-up (PDFU) with 95% confidence intervals. The cumulative incidence functions of secondary infections according to thrombotic complications were compared with Grayâs method accounting for competing risk of death. A multivariable Fine-Gray model was applied to assess factors associated with risk of secondary infections. Results. Overall, 109/904 patients had 176 secondary infections (IR, 10.0; 95% CI, 8.8â11.5; per 1000-PDFU). The IRs of secondary infections among patients with or without thrombotic complications were 15.0 (95% CI, 10.7â21.0) and 9.3 (95% CI, 7.9â11.0) per 1000-PDFU, respectively (P = .017). At multivariable analysis, thrombotic complications were associated with the development of secondary infections (subdistribution hazard ratio, 1.788; 95% CI, 1.018â3.140; P = .043). The etiology of secondary infections was similar in patients with and without thrombotic complications. Conclusions. In patients with COVID-19, thrombotic complications were associated with a high risk of secondary infections
- âŠ